These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21860100)

  • 1. Antibiotic resistance in ocular bacterial pathogens.
    Sharma S
    Indian J Med Microbiol; 2011; 29(3):218-22. PubMed ID: 21860100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.
    McDonald M; Blondeau JM
    J Cataract Refract Surg; 2010 Sep; 36(9):1588-98. PubMed ID: 20692574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study.
    Haas W; Pillar CM; Torres M; Morris TW; Sahm DF
    Am J Ophthalmol; 2011 Oct; 152(4):567-574.e3. PubMed ID: 21652021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular bacterial infections: current and future treatment options.
    Kowalski RP; Dhaliwal DK
    Expert Rev Anti Infect Ther; 2005 Feb; 3(1):131-9. PubMed ID: 15757463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002.
    Morrissey I; Burnett R; Viljoen L; Robbins M
    J Infect; 2004 Aug; 49(2):109-14. PubMed ID: 15236917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.
    Sanfilippo CM; Morrissey I; Janes R; Morris TW
    Curr Eye Res; 2016 May; 41(5):581-9. PubMed ID: 26200173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriologic profile of the conjunctiva in the patients with dry eye.
    Hori Y; Maeda N; Sakamoto M; Koh S; Inoue T; Tano Y
    Am J Ophthalmol; 2008 Nov; 146(5):729-34. PubMed ID: 18672220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Besifloxacin in the management of bacterial infections of the ocular surface.
    Deschênes J; Blondeau J
    Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical antibiotic therapy in eye infections - myths and certainties in the era of bacterial resistance to antibiotics.
    Aramă V
    Rom J Ophthalmol; 2020; 64(3):245-260. PubMed ID: 33367158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
    Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to ocular antibiotics: an overview.
    Brown L
    Clin Exp Optom; 2007 Jul; 90(4):258-62. PubMed ID: 17535364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The food safety perspective of antibiotic resistance.
    McDermott PF; Zhao S; Wagner DD; Simjee S; Walker RD; White DG
    Anim Biotechnol; 2002 May; 13(1):71-84. PubMed ID: 12212946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
    O'Brien TP
    Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance.
    Lieberman JM
    Pediatr Infect Dis J; 2003 Dec; 22(12):1143-51. PubMed ID: 14688589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of bacterial isolates from corneal specimens and their antibiotic resistance profile.
    Begum NN; Al-Khattaf AS; Al-Mansouri SM; Yeboah EA; Kambal AM
    Saudi Med J; 2006 Jan; 27(1):41-5. PubMed ID: 16432592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
    Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
    Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS; Zhang JZ
    Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis.
    Sueke H; Kaye S; Neal T; Murphy C; Hall A; Whittaker D; Tuft S; Parry C
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2519-24. PubMed ID: 20019362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.